Recently, our group has designed and characterized neurotinib, a new c-Abl allosteric inhibitor binding at the myristoyl pocket of the kinase with excellent BBB permeability and brain pharmacokinetics, and showed that neurotinib decreases cognitive decline in Niemann-Pick A mice (Marin et al., 2022). This evidence concerns the gene ABL1 and Mental deterioration.